I. Craig Henderson
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies 65
- Cancer Genomics and Diagnostics 9
- Oncology top 0.1%
- Cancer Treatment and Pharmacology 50
- HER2/EGFR in Cancer Research 25
- Global Cancer Incidence and Screening 12
- Pathology and Forensic Medicine top 0.5%
- Breast Lesions and Carcinomas 20
- Genetics top 1%
-
- Chemotherapy-induced cardiotoxicity and mitigation 14
-
- Cancer therapeutics and mechanisms 13
- Co-authors
- Larry NortonDonald A. BerryHyman B. MussConstance CirrincioneRebecca GelmanDaniel F. HayesClifford A. HudisJay R. Harris
- Partner nations
- United StatesCanadaSwitzerland
In The Last Decade
I. Craig Henderson
152 papers receiving 11.2k citations
Hit Papers
Peers
Comparison fields: 5 of 146
- Cancer Research 5.2k
- Oncology 7.5k
- Pathology and Forensic Medicine 1.7k
- Radiology, Nuclear Medicine and Imaging 1.8k
- Genetics 1.5k
Countries citing papers authored by I. Craig Henderson
This map shows the geographic impact of I. Craig Henderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Craig Henderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Craig Henderson more than expected).
Fields of papers citing papers by I. Craig Henderson
This network shows the impact of papers produced by I. Craig Henderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Craig Henderson. The network helps show where I. Craig Henderson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside I. Craig Henderson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Can we abandon anthracyclines for early breast cancer patients? | 2011 | 12 |
| 2 | 2008 | 7 | |
| 3 | 2007 | 94 | |
| 4 | 2006 | 24 | |
| 5 | 2005 | 82 | |
| 6 | Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancerbreakdown → | 2004 | 733 |
| 7 | New Horizons in research and Treatment | 2001 | 3 |
| 8 | Breast cancer : new horizons in research and treatment | 2001 | 10 |
| 9 | Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. | 2001 | 75 |
| 10 | 2000 | 146 | |
| 11 | Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. | 1999 | 229 |
| 12 | Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.breakdown → | 1996 | 1088 |
| 13 | 1993 | 109 | |
| 14 | 1991 | 1 | |
| 15 | 1990 | 36 | |
| 16 | 1990 | 2 | |
| 17 | 1990 | 4 | |
| 18 | 1989 | 110 | |
| 19 | 1989 | 5 | |
| 20 | 1984 | 3 |
About I. Craig Henderson
I. Craig Henderson is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 153 papers that have together received 11.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (65 papers), Cancer Treatment and Pharmacology (50 papers), HER2/EGFR in Cancer Research (25 papers), Breast Lesions and Carcinomas (20 papers), Chemotherapy-induced cardiotoxicity and mitigation (14 papers), Cancer therapeutics and mechanisms (13 papers), Global Cancer Incidence and Screening (12 papers) and Cancer Genomics and Diagnostics (9 papers). The work is most often cited by research in Cancer Research (5.2k citations), Oncology (7.5k citations) and Pathology and Forensic Medicine (1.7k citations). I. Craig Henderson has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Larry Norton, Donald A. Berry, Hyman B. Muss, Constance Cirrincione, Rebecca Gelman, Daniel F. Hayes, Clifford A. Hudis, Jay R. Harris, Daniel R. Budman and Eric P. Winer. Their work appears in journals such as Nature, New England Journal of Medicine and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.